Search for metabolomic markers of hypertensive conditions of different genesis: Experimental study-Reference-Cited by-同舟云学术

Search for metabolomic markers of hypertensive conditions of different genesis: Experimental study

Published:2024-08-29 Issue:1 Volume:60 Page:12-23
ISSN:0044-4529
Container-title:Журнал эволюционной биохимии и физиологии
language:
Short-container-title:Žurnal èvolûcionnoj biohimii i fiziologii

Author:

Seryapina А. А.¹,Sorokoumova А. А.¹,Polityko Yu. К.¹²,Yanshole L. V.³,Tsentalovich Yu. P.³,Gilinsky М. А.²,Markel А. L.¹⁴

Affiliation:

1. Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences

2. Federal State Budgetary Scientific Institution “Research Institute of Neuroscience and Medicine”

3. Institute “International Tomographic Center”, Siberian Branch of the Russian Academy of Sciences

4. Novosibirsk State University

Abstract

A personalized approach to the diagnosis and treatment of arterial hypertension requires a comprehensive analysis of the pathogenetic mechanisms underlying the disease. To determine specific metabolomic markers of various hypertensive conditions, four groups of experimental animals were studied: WAG rats (normotensive control); ISIAH rats with inherited stress-induced arterial hypertension (AH); L-NAME-treated rats with hypertension induced by endothelial dysfunction; rats with hypertension caused by DOCA administration in combination with the salt loading. Rat blood serum samples were analyzed by NMR spectroscopy. The metabolomic analysis differentiated the hypertensive conditions of various origins using group-specific blood serum metabolomic biomarkers. Rats with DOCA-salt hypertension are characterized by increased concentration of choline. Hypertension associated with endothelial dysfunction induced by L-NAME administration was accompanied by a decrease in the levels of tyrosine, serine and glycine. Distinctive features of ISIAH rats are increased concentrations of ornithine (urea and nitric oxide cycle), valine, leucine, isoleucine, myo-inositol, glutamate, glutamine (glucose metabolism).

Publisher

The Russian Academy of Sciences

Reference50 articles.

1. Byrd JB (2016) Personalized medicine and treatment approaches in hypertension: current perspectives. Integr Blood Press Contr 9: 59–67. https://doi.org/10.2147/IBPC.S74

2. De Jong W, Birkenhäger WH, Reid JL (Eds) (2013) Experimental and Genetic Models of Hypertension. Handbook of Hypertension, Elsevier.

3. Schenk J, McNeill JH (1992) The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Meth 27(3): 161–170. https://doi.org/10.1016/1056-8719(92)90036-Z

4. Küng CF, Moreau P, Takase H, Lüscher TF (1995) L-NAME hypertension alters endothelial and smooth muscle function in rat aorta: prevention by trandolapril and verapamil. Hypertension 26(5): 744–751. https://doi.org/10.1161/01.HYP.26.5.744

5. Markel AL (1992) Development of a new strain of rats with inherited stress-induced arterial hypertension. In Genetic Hypertension. (Ed.J. Sassard), Colloque INSERM John Libbey Eurotext Ltd 218: 405–407.